July 2016

New Product - Signifor LAR

Signifor LAR (pasireotide (embonate)) is a cyclohexapeptide, injectable somatostatin analogue. Like natural peptide hormones somatostatin‑14 and somatostatin‑28 (also known as somatotropin release inhibiting factor (SRIF)) and other somatostatin analogues, pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). Pasireotide binds with high affinity to four of the five SSTRs. Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues. Signifor LAR is contraindicated in severe hepatic impairment (Child Pugh C). Signifor LAR is available as 20 mg, 40 mg and 60 mg powder for injection vial in packs of 1’s (also with one prefilled syringe containing diluent, one vial adaptor and one safety injection).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629